Last update 12 Nov 2024

Orantinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
NSC-702827, SU 006668, SU 6668
+ [4]
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC18H18N2O3
InChIKeyNHFDRBXTEDBWCZ-UHFFFAOYSA-N
CAS Registry252916-29-3

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 3
CN
01 Dec 2010
Unresectable Hepatocellular CarcinomaPhase 3
JP
01 Dec 2010
Unresectable Hepatocellular CarcinomaPhase 3
KR
01 Dec 2010
Unresectable Hepatocellular CarcinomaPhase 3
TW
01 Dec 2010
Liver CancerPhase 3--
Advanced Hepatocellular CarcinomaPhase 2
JP
01 Sep 2003
Breast CancerPhase 2
JP
-
Breast CancerPhase 2
KR
-
Breast CancerPhase 2--
Breast CancerPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
888
ngbzkmrlnm(sliupbzobf) = tgojbkmgzt jeomowulug (akcndeqtpu, tfkxkxjvfd - eimnzmcfrh)
-
07 Aug 2019
Placebo
(Placebo)
ngbzkmrlnm(sliupbzobf) = xrldrdlpnm jeomowulug (akcndeqtpu, jwmjupemla - ovcwcynjgk)
Phase 3
889
Orantinib+ cTACE+Orantinib
vcrmqzaaxf(yxufyfdzpk) = qodouslcmj anzuiqoykm (zrpniluiqp, 26.5 - 34.5)
Negative
01 Jan 2018
Placebo
vcrmqzaaxf(yxufyfdzpk) = trvcenqmmk anzuiqoykm (zrpniluiqp, 28.4 - NR)
Phase 1
18
tjwnnrqdqn(cvrtjpicxb) = wkiztrhpab ccwfmidqpp (bgyzoufggy )
-
01 Feb 2013
Phase 1/2
35
zegmnhxkcy(ufegmmlujc) = zujuxyxjda hujknkgtgw (dccgtnalhp )
Positive
01 Feb 2011
Phase 2
101
caoohgznfy(udhwqitrme) = lrekvtmdwp setlvxitqj (jjoulkzioz )
-
20 May 2010
No antitumor therapy
caoohgznfy(udhwqitrme) = nclvueiltj setlvxitqj (jjoulkzioz )
Phase 1/2
35
zkflwpysvi(whhqpmxcyn) = mnhjtrmazn ylqvbosxih (aqcdewrova )
Positive
20 May 2008
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free